Intronn Overview

  • Year Founded
  • 1988

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 11

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 5

Intronn General Information

Description

Developer of spliceosome-mediated RNA trans-splicing (SMaRT) technology. The company has produced a series of PTMs capable of base-pairing to and trans-splicing with disease associated pre-mRNA targets.

Contact Information

Website
www.intronn.com
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • 910 Clopper Road
  • South Building, Suite 210
  • Gaithersburg, MD 20878
  • United States
+1 (240)
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Virxsys
Vertical(s)
Life Sciences
Corporate Office
  • 910 Clopper Road
  • South Building, Suite 210
  • Gaithersburg, MD 20878
  • United States
+1 (240)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Intronn Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Intronn‘s full profile, request access.

Request a free trial

Intronn Patents

  • 21

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Intronn Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2003256606-A1 Spliceosome mediated rna trans-splicing for correction of skin disorders Inactive 17-Jul-2002
EP-1542532-A1 Spliceosome mediated rna trans-splicing for correction of skin disorders Inactive 17-Jul-2002
CA-2492469-A1 Spliceosome mediated rna trans-splicing for correction of skin disorders Inactive 17-Jul-2002
EP-1549755-A2 Spliceosome mediated rna trans-splicing in stem cells Inactive 05-Jun-2002
EP-1521766-A2 Spliceosome mediated rna i trans /i -splicing and correction of factor viii genetic defects using spliceosome mediated rna trans spling Active 05-Jun-2002 C07K14/755
To view Intronn’s complete patent history, request access »

Intronn Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Intronn Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Intronn‘s full profile, request access.

Request a free trial

Intronn FAQs

  • When was Intronn founded?

    Intronn was founded in 1988.

  • Where is Intronn headquartered?

    Intronn is headquartered in Gaithersburg, MD.

  • What is the size of Intronn?

    Intronn has 11 total employees.

  • What industry is Intronn in?

    Intronn’s primary industry is Biotechnology.

  • Is Intronn a private or public company?

    Intronn is a Private company.

  • What is Intronn’s current revenue?

    The current revenue for Intronn is .

  • How much funding has Intronn raised over time?

    Intronn has raised $11M.

  • Who are Intronn’s investors?

    AEA Investors, Maryland Industrial Partnerships, and Research Corporation Technologies have invested in Intronn.

  • When was Intronn acquired?

    Intronn was acquired on 21-Sep-2007.

  • Who acquired Intronn?

    Intronn was acquired by Virxsys.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »